304 North Cardinal St.
Dorchester Center, MA 02124
WhatWWProduct name: Osimert
Brand name: Tagrisso
Generic name: osimertinib
Quantity: 30 tablets
Manufacturer: Everest Pharmaceuticals Bangladesh.
Osimert-80mg-Osimertinib is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). Which has been developed by AstraZeneca Pharmaceuticals for treating metastatic non-small cell lung cancer (NSCLC) where tumor EGFR expression is positive for the T790M mutation. Approximately 10% of patients with NSCLC have a rapid and clinically effective response to EGFR-TKIs due to specific activating EGFR mutations.
The third-generation EGFR-TKIs were developed to address altered tumor resistance patterns and toxic side effects that impact patient quality of life. First-generation EGFR-TKIs, such as gefitinib and erlotinib, have been associated with resistance and increased toxicity. Osimert-80mg-Osimertinib, on the other hand, is specific for the gate-keeper T790M mutations, reducing ATP binding activity and limiting toxicity. 1
Osimert-80mg-Osimertinib is a medication that is used as adjuvant therapy after the removal of tumors in adult patients with non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations (as detected by an FDA-approved test). It is also the first-line treatment for adult patients with metastatic NSCLC whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations (as detected by an FDA-approved test). Additionally, Osimert-80mg is indicated for the treatment of adult patients with metastatic EGFR T790M mutation-positive NSCLC, as detected by an FDA-approved test, whose disease has progressed on or after EGFR TKI therapy. 2
Osimert-80mg is a third-generation tyrosine kinase inhibitor that targets specific mutant forms of EGFR in non-small cell lung cancer (NSCLC) tumors. It is specific for the T790M mutation, which increases ATP binding activity and leads to poor prognosis. Osimert-80mg spares wild-type EGFR during therapy, reducing non-specific binding and limiting toxicity. In vitro, it has a 200 times higher affinity for EGFR molecules with the L858R/T790M mutation.
|Adjuvant treatment for NSCLC with EGFR exon 19 deletions or exon 21 L858R mutations||80 mg PO once daily||lf disease recurrence, unacceptable toxicity, or for up to 3 years first|
|t-line treatment for metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R mutations||80 mg PO once daily||Until disease progression or unacceptable toxicity|
|Previously treated metastatic NSCLC with EGFR T790M mutation-positive NSCLC||80 mg PO once daily||Until disease progression or unacceptable toxicity|
Osimert-80mg tablets can be taken with or without food. Swallow the tablets whole with water. Do not chew, crush, or break the tablets.
If you miss a dose of Osimert-80mg, take it as soon as you remember. If it is almost time for your next dose, skip the missed dose and take your next dose at the scheduled time. Do not take a double dose to make up for a missed dose. 3
Osimert-80mg is a medication with common side effects including diarrhea, nausea, vomiting, fatigue, rash, dry skin, itching, decreased appetite, mouth sores, headache, constipation, cough, and shortness of breath.
Other possible side effects include liver, kidney, lung, heart, blood, eye, skin, muscle, and bone problems, nervous system problems, reproductive system problems, and allergic reactions.
The multicenter phase 2 trial assessed the safety and efficacy of Osimert-80mg and platinum-based chemotherapy in patients with untreated EGFR-mutated advanced non-squamous NSCLC.
Patients were given Osimert-80mg daily with cisplatin or carboplatin, plus pemetrexed for four cycles, and maintenance therapy with pemetrexed every 3 weeks. Primary end-points included safety and objective response rate, while secondary end-points included complete response rate, disease control rate, and progression-free survival.
Between July 2019 and February 2020, 67 patients were enrolled in a study. At the data cutoff, 52.2% discontinued the protocol treatment, with 14.9% due to adverse events. No treatment-related deaths occurred. The ORR, CRR, and DCR were 90.9%, 3.0%, and 97.0%, respectively. The median follow-up time was 33.4 months, with a median PFS of 31.0 months.
RYBREVANT is a bispecific antibody that targets both EGFR and MET. Osimert-80mg is a third-generation EGFR tyrosine kinase inhibitor (TKI). Both drugs are used to treat non-small cell lung cancer (NSCLC) with specific EGFR mutations.
There are a few ongoing clinical trials evaluating the use of RYBREVANT in combination with Osimert-80mg for the treatment of NSCLC. One trial, called MARIPOSA, is comparing the efficacy and safety of RYBREVANT and lazertinib (another third-generation EGFR TKI) in combination with osimertinib to osimertinib alone in the first-line treatment of patients with NSCLC with EGFR exon 19 deletions or exon 21 L858R mutations. Another trial, called MARIPOSA-2, is evaluating the efficacy and safety of RYBREVANT and lapatinib in combination with platinum-based chemotherapy in patients with NSCLC with EGFR exon 19 deletions or exon 21 L858R mutations after disease progression on or after osimertinib.
The results of these trials are not yet available. However, they could provide important information about the potential benefits of using RYBREVANT in combination with Osimert-80mg for the treatment of NSCLC.
In the meantime, the use of RYBREVANT in combination withOsimert-80mgosimertinib is considered off-label. This means that it is not approved by the FDA for this use. However, some doctors may prescribe RYBREVANT in combination with Osimert-80mg for patients with NSCLC who have progressed on osimertinib alone or who cannot tolerate other treatments.
The cost for Tagrisso oral tablet 40 mg is around $16,999 for a supply of 30 tablets, depending on the pharmacy you visit. Quoted prices are for cash-paying customers and are not valid with insurance plans. This price guide is based on using the Drugs.com discount card which is accepted at most U.S. pharmacies.
But Osimert-80mg is the same medicine at a very low price. Bangladeshi renowned pharmaceutical Everest Pharma is the manufacturer and supplier of this medicine. You can Collect this medicine for around $300. Contact us for order.
Visit the Shop Page.